Revenue: As of FY2025 Q3, the actual value is USD 0.EPS: As of FY2025 Q3, the actual value is USD -0.07.EBIT: As of FY2025 Q3, the actual value is USD -682.12 K.<h3>Segment Revenue</h3><ul><li>The company did not generate revenue during the three and nine months ended September 30, 2025 and 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: For the three months ended September 30, 2025, the net loss was $1,823,351, compared to $601,372 for the same period in 2024, representing a 203% increase.</li><li>Loss from Operations: For the nine months ended September 30, 2025, the loss from operations was $2,083,601, compared to $3,162,876 for the same period in 2024, representing a 34% decrease.</li><li>General and Administrative Expenses: Increased by $515,089 during the three months ended September 30, 2025 compared to the same period in 2024, primarily due to increased accounting and legal expenses.</li><li>Research and Development Expenses: Decreased by $357,066 during the three months ended September 30, 2025 compared to the same period in 2024 due to the termination of TDT’s license agreements.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used in operating activities was $9,576,471, compared to $1,310,406 for the same period in 2024, representing a 631% increase.</li><li>Net Cash Used in Investing Activities: For the nine months ended September 30, 2025, net cash used in investing activities was $788,108, compared to $2,300,000 for the same period in 2024, representing a 66% decrease.</li><li>Net Cash Provided by Financing Activities: For the nine months ended September 30, 2025, net cash provided by financing activities was $11,032,762, compared to $3,223,000 for the same period in 2024, representing a 242% increase.</li></ul><h3>Unique Metrics</h3><ul><li>Forgiveness of Unrelated Vendor Payables: The company recognized a gain of $2,142,297 related to the settlement of TDT’s payables during the nine months ended September 30, 2025.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to raise additional cash through equity and debt financings or other arrangements to fund operations. There is substantial doubt about its ability to continue as a going concern for one year after the date that the accompanying unaudited condensed consolidated financial statements are issued.</li><li>Non-Core Business: The company has terminated its license agreements with TDT for CAR-T and Vaccine Products, and settled related payables, which may impact future research and development activities.</li></ul>

LIMINATUS PHARMA INC C/WTS 30/04/2030 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 0